Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
About this item
Full title
Author / Creator
Langley, Richard G , Elewski, Boni E , Lebwohl, Mark , Reich, Kristian , Griffiths, Christopher E.M , Papp, Kim , Puig, Lluís , Nakagawa, Hidemi , Spelman, Lynda , Sigurgeirsson, Bárður , Rivas, Enrique , Tsai, Tsen-Fang , Wasel, Norman , Tyring, Stephen , Salko, Thomas , Hampele, Isabelle , Notter, Marianne , Karpov, Alexander , Helou, Silvia , Papavassilis, Charis , FIXTURE Study Group and ERASURE Study Group
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In two trials in patients with moderate-to-severe plaque psoriasis, the anti–interleukin-17A monoclonal antibody secukinumab was more effective than placebo and etanercept. Infectious complications occurred more often with secukinumab than with placebo.
Psoriasis is a chronic, immune-mediated inflammatory skin disease that is associated with sub...
Alternative Titles
Full title
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
Authors, Artists and Contributors
Author / Creator
Elewski, Boni E
Lebwohl, Mark
Reich, Kristian
Griffiths, Christopher E.M
Papp, Kim
Puig, Lluís
Nakagawa, Hidemi
Spelman, Lynda
Sigurgeirsson, Bárður
Rivas, Enrique
Tsai, Tsen-Fang
Wasel, Norman
Tyring, Stephen
Salko, Thomas
Hampele, Isabelle
Notter, Marianne
Karpov, Alexander
Helou, Silvia
Papavassilis, Charis
FIXTURE Study Group
ERASURE Study Group
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1548633805
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1548633805
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1314258
